U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®

Stock Information for Crescita Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescita Therapeutics Inc.

Crescita Reports Q4 and Fiscal 2023 Results
Crescita Reports Third Quarter 2023 Results
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita Reports Second Quarter 2023 Results
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
Crescita Reports First Quarter 2023 Results
Crescita Reports Q4 and Fiscal 2022 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.